PACT Pharma
News Center

Latest News & Updates

We are hard at work developing personalized T cell therapies for people living with cancer. Explore our latest news and updates.

Press Releases
In the News
Abstracts & Publications

Leap forward' in tailored cancer medicine


Retrospective Tumor Microenvironment Analysis from a Personalized neoTCR-T Cell Therapy Clinical Trial and Its Potential Applications for Off-the-Shelf HPV TCR T Cell Therapy


Rapid identification of a TCR library targeting the HPV E6/E7 oncoproteins to enable multi-TCR T cell therapies for patients with HPV+ epithelial cancers


PACT Pharma Reports Data From First Clinical Study Using CRISPR to Substitute a Gene in Patients’ Immune Cells to Treat Cancer

PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR)-T cell therapies for the eradication of solid tumors, today reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients’ immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT’s proprietary platforms, demonstrated early proof-of-concept that a patient’s immune system can be reprogrammed to recognize their own cancer. The study findings were the focus of a late breaking oral presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), as well as a peer-reviewed paper in Nature that was published in conjunction with SITC 2022.


A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

Load More